ArticleNeuro-oncology2026
CNS tumor type prevalence according to age group: An analysis of 21 000 cases confirmed by methylation profiling, with a focus on adolescents and young adults.
Adriana Fonseca, Leeor Yefet, Omkar Singh, Christopher Dampier, Karen Dazelle, Michelle Lam, Zied Abdullaev, Hye-Jung Chung, Martha Quezado, Mark Raffeld and 14 more
Abstract read
In one paragraphArticle in Neuro-oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from itWhat it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
24 authors.
Adriana FonsecaBrain Tumor Institute, Children's National Hospital, Washington, District of Columbia, USA.ORCID 0000-0002-6382-6833 Leeor YefetDepartment of Neurosurgery, Mayo Clinic, Rochester, Minnesota, USA.
Omkar SinghLaboratory of Pathology, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, USA.ORCID 0000-0002-4500-7519 Christopher DampierLaboratory of Pathology, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, USA.ORCID 0000-0003-3099-6462 Karen DazelleLaboratory of Pathology, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, USA.ORCID 0009-0006-1357-2384 Michelle LamLaboratory of Pathology, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, USA.ORCID 0009-0009-2167-506X Zied AbdullaevLaboratory of Pathology, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, USA.ORCID 0000-0001-6345-2088 Hye-Jung ChungLaboratory of Pathology, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, USA.
Martha QuezadoLaboratory of Pathology, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, USA.ORCID 0009-0004-0941-8662 Mark RaffeldLaboratory of Pathology, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, USA.ORCID 0000-0002-4039-6957 Jeffrey GaganLaboratory of Pathology, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, USA.ORCID 0000-0003-4676-9969 Ina LeeLaboratory of Pathology, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, USA.ORCID 0000-0002-6082-6395 MacLean NasrallahDivision of Neuropathology, Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.ORCID 0000-0003-4861-0898 Julie BennettDivision of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, Ontario, Canada.ORCID 0000-0002-4146-1511 Dipak PoriaBrain Tumor Institute, Children's National Hospital, Washington, District of Columbia, USA.ORCID 0000-0002-6935-4160 Pieter WesselingDepartment of Pathology, Amsterdam University Medical Centers/VU University Medical Center, Amsterdam, The Netherlands.ORCID 0000-0001-5453-5201 Martin van den BentDepartment of Neurology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.ORCID 0000-0001-5710-5127 Patrick Y WenCenter for Tumors of the Nervous System, Mass General Brigham Cancer Institute, Boston, Massachusetts, USA (P.Y.W.).ORCID 0000-0002-0774-7700 Pascale VarletDepartment of Neuropathology, GHU Paris - Psychiatry and Neuroscience, Sainte-Anne Hospital, Paris, France.ORCID 0000-0002-8164-1517 Arnault Tauziède-EspariatDepartment of Neuropathology, GHU Paris - Psychiatry and Neuroscience, Sainte-Anne Hospital, Paris, France.ORCID 0000-0002-9979-0297 Cristiane M IdaDepartment of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA.ORCID 0000-0003-2768-2913 Kenneth AldapeLaboratory of Pathology, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, USA.ORCID 0000-0001-5119-7550 Funding
Single-cell DNA methylation analysis of human cancerZIABC011846 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI ALDAPE, KENNETH · 2018 to 2025
$8.4MChildren's National Hospital, Brain Tumor InstituteIntramural NIH HHS ZIA BC011846NIH HHS 1ZIABC011846
6 · The paper itselfAbstract
backgroundApproximately 12 000 adolescents and young adults (ages 15-39, AYAs) are diagnosed with a primary central nervous system (CNS) tumor each year. DNA methylation profiling has transformed CNS tumor classification by refining diagnostic accuracy and identifying biologically distinct subtypes, but its application has not been systematically evaluated in the AYA population. In this study, we examined the spectrum of CNS tumor types across age groups, with a focus on the AYA population.
methodsWe assembled a large dataset of CNS tumor samples with age annotations and methylation profiles matching with high confidence to a CNS tumor type using the NCI/Bethesda classifier. Prevalence of tumor type, methylation class and DNA copy number aberrations were compared across age strata (pediatric, AYA, and adult).
resultsThe cohort of 21 712 CNS tumors included 5351 tumors from AYAs (25%), which showed a mixed pattern, with tumors typical of childhood (eg, medulloblastoma) as well as those common in older adults (eg, glioblastoma). Several tumor types were specifically enriched in the AYA, including IDH-mutant astrocytoma, pleomorphic xanthoastrocytoma, posterior fossa group B ependymoma, and diffuse hemispheric glioma, H3 G34-mutant, among others. Distinct methylation subclasses of multiple tumor types were observed in the AYA, and patterns of genomic aberrations showed age-specific distributions.
conclusionLarge-scale methylation profiling revealed unique classification patterns of CNS tumors in AYAs, with specific tumor types, subclasses, and genomic alterations enriched in this population. These data may serve as a valuable reference resource for better understanding the spectrum of CNS tumors affecting AYA patients.
Indexed as
Biomarkers, TumorCentral Nervous System NeoplasmsDNA MethylationAdolescentAdultAge FactorsChildFemaleHumansMalePrevalencePrognosisYoung AdultBiomarkers, Tumoradolescents and young adultsAYADNA methylation classificationtumor types
Identifiers
PMID41978543
PMCPMC13255572
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390